MEDIA RELEASES
_ Major cooperation agreement for development of preclinical candidate for the treatment of anaemia
_ Galenica 2009: significant investments for future success
_ FAIR-HF study results show significant improvement in Chronic Heart Failure patients’ lives and give a new therapeutic option to healthcare professionals
_ Ferinject®: FAIR-HF study meets primary endpoints in patients with Iron Deficiency and Chronic Heart Failure
_ David Ebsworth becomes a new member of the Corporate Executive Committee of Galenica and CEO of Vifor Pharma
_ Galenica expands its pharma business:
Acquisition of the Swiss biotechnology and pharmaceutical company OM PHARMA
_ Galenica: Earnings up 10.5% despite major challenges
_ Integration of Aspreva completed - Vifor Pharma enters into a new phase
_ Annual General Meeting of Galenica Ltd. on 14 May 2009: Jacques Theurillat steps down from the Board of Directors
_ Competition Commission approves the acquisition of Sun Store
_ Integration of Globopharm:
Prewholesale activities to be transferred to Alloga in Burgdorf
_ 2008 Results for the Galenica Group
_ Galenica acquires Sun Store
_ Galenica 2008: a very successful year with an outstanding result expected
_ Galenica strengthens its logistics business
_ Venofer®: Closing of the agreement between Fresenius Medical Care and Luitpold Pharmaceuticals, Inc.
_ New partnership in the UK and Ireland
_ Official opening of the Galexis distribution centre in Niederbipp
_ Results of the Galenica Group for the first half of 2008
_ Investigation by Competition Commission concluded
_ Galenica: strategic joint-venture with Fresenius Medical Care
_ Galenica promising launch for Ferinject® in Europe
_ Galenica to establish its market position in Northern Europe
_ Annual General Meeting of Galenica Ltd.:
Shareholders approve all proposals of the Board of Directors
_ New record result for Galenica: Profit up 30%!
_ Injectafer® (Ferinject®): non-approvable letter received from the FDA
_ Injectafer® (Ferinject®): Recommendation of the FDA Advisory Committee, Recommendation for approval when oral iron treatment is ineffective
_ Statement: FDA Advisory Committee on February 1, 2008
_ Galenica in 2007: a new record year for strategy and business
_ Takeover transaction for Aspreva closed